EIGR - Eiger Biopharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart

Eiger Biopharmaceuticals's activity chart (see below) currently has 51 price targets and 39 ratings on display.

Stock Analyst Price Targets - Review

Most recent stock forecast was given by YIGAL NOCHOMOVITZ from CITI on 29-Aug-2023. First documented stock forecast 27-Apr-2015.

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 26-Jun-2019

$120

3 years 2 months 24 days ago
(29-Aug-2023)

0/4 (0%)

$81.6 (212.50%)

Buy Since 09-May-2018

$150

3 years 4 months 23 days ago
(30-Jun-2023)

0/2 (0%)

$128.88 (610.23%)

Buy Since 09-Dec-2022

$90

$90

3 years 6 months 7 days ago
(15-May-2023)

0/2 (0%)

$52.2 (138.10%)

Buy Since 14-Jul-2017

$270

$1440

3 years 11 months 10 days ago
(12-Dec-2022)

0/5 (0%)

$231.6 (603.13%)

Buy Since 19-Oct-2017

$870

$690

4 years 8 months 5 days ago
(17-Mar-2022)

0/4 (0%)

$630.6 (263.41%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which analyst most recently updated their price target on EIGR (Eiger Biopharmaceuticals)?

Yigal Nochomovitz

Which analyst has the most public recommendations on EIGR (Eiger Biopharmaceuticals)?

Yigal Nochomovitz works at CITI and has 38 price targets and 23 ratings on EIGR

Which analyst is the currently most bullish on EIGR (Eiger Biopharmaceuticals)?

David Nierengarten with the highest potential upside of $1077.95

Which analyst is the currently most reserved on EIGR (Eiger Biopharmaceuticals)?

Yigal Nochomovitz with the lowest potential downside of -$0
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?